Rivoltini L, Barracchini K C, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo N P, Topalian S L, Simonis T B, Rosenberg S A
Surgery Branch, Clinical Oncology Program, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
Cancer Res. 1995 Jul 15;55(14):3149-57.
MHC class I antigen expression is necessary for CD8+ T-cell-mediated recognition of tumors. Recently, several mechanisms leading to loss or decreased expression of MHC antigens on the tumor cell surface have been described that may account for tumor escape from immune recognition. It is yet unknown whether tumor recognition by CTL occurs at a threshold amount of MHC molecules or correlates with the level of HLA-allele expression. In this study, a model was developed in which clones derived from the 624-MEL melanoma cell line and expressing varying amounts of HLA-A2 molecules were lysed in a standard 51Cr release assay by an HLA-A2-restricted CTL clone (A42) or a bulk culture of tumor-infiltrating lymphocytes. The A42 clone and the tumor-infiltrating lymphocyte culture were characterized previously as specifically recognizing the melanoma antigen MART-1(27-35) peptide. A marked heterogeneity in the susceptibility to lysis by A42 was observed in tumor clones and was not due to heterogeneous expression of MART-1 by the clones or loss of accessory molecules involved in the lymphocyte-target interaction. Lysis by A42 and by the tumor-infiltrating lymphocyte culture significantly correlated with the level of HLA-A2 expression, evaluated as mean channel number of fluorescence by flow cytometry (P < 0.001). Transfection of an HLA-A2-negative clone (624.28) with the HLA-A2.1 gene produced a panel of clones expressing different levels of HLA-A2, the lysis of which was highly correlated with the expression of HLA-A2 (P < 0.001). The addition of exogenous MART-1(27-35) peptide enhanced lysis of clones expressing intermediate amounts of HLA-A2 but did not affect clones with high expression. These data suggest that the number of HLA molecules present on the surface of tumor cells can quantitatively affect their lysis by CTL in situations with borderline amounts of peptide and/or MHC.
MHC I类抗原表达对于CD8 + T细胞介导的肿瘤识别是必需的。最近,已经描述了几种导致肿瘤细胞表面MHC抗原丢失或表达降低的机制,这些机制可能解释了肿瘤如何逃避免疫识别。目前尚不清楚CTL对肿瘤的识别是发生在MHC分子的阈值量时,还是与HLA等位基因的表达水平相关。在本研究中,构建了一个模型,其中来源于624-MEL黑色素瘤细胞系并表达不同量HLA-A2分子的克隆,在标准的51Cr释放试验中被HLA-A2限制性CTL克隆(A42)或肿瘤浸润淋巴细胞的大量培养物裂解。A42克隆和肿瘤浸润淋巴细胞培养物先前被鉴定为特异性识别黑色素瘤抗原MART-1(27 - 35)肽。在肿瘤克隆中观察到对A42裂解的敏感性存在显著异质性,这不是由于克隆中MART-1的异质表达或淋巴细胞-靶细胞相互作用中涉及的辅助分子的丢失。A42和肿瘤浸润淋巴细胞培养物的裂解与HLA-A2表达水平显著相关,通过流式细胞术评估为荧光平均通道数(P < 0.001)。用HLA-A2.1基因转染HLA-A2阴性克隆(624.28)产生了一组表达不同水平HLA-A2的克隆,其裂解与HLA-A2的表达高度相关(P < 0.001)。添加外源性MART-1(27 - 35)肽增强了表达中等量HLA-A2的克隆的裂解,但不影响高表达的克隆。这些数据表明,在肽和/或MHC量处于临界水平的情况下,肿瘤细胞表面存在的HLA分子数量可以定量地影响其被CTL裂解的程度。